Turn Therapeutics (NASDAQ:TTRX) Raised to "Hold" at Wall Street Zen

Key Points

• Wall Street Zen upgraded Turn Therapeutics from “Sell” to “Hold.” Despite mixed analyst opinions, the stock has a consensus “Moderate Buy” rating and an $8.00 price target.
• Turn Therapeutics shares were trading down 5.2% at $12.69, well above their 52-week low of $2.57 but below the high of $26.50. The company reported a quarterly loss of $0.20 per share and analysts expect a full-year loss of $0.40 per share.
• Several institutional investors recently established or expanded positions, including Ieq Capital, Millennium Management, BlackRock and DDFG.

Turn Therapeutics (NASDAQ:TTRX - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued on Sunday, Wall Street Zen reports.

TTRX has been the topic of a number of other reports. Weiss Ratings lowered Turn Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday, August 18th. LADENBURG THALM/SH SH raised shares of Turn Therapeutics to a "strong-buy" rating in a research note on Monday, July 20th. Finally, Zacks Research upgraded shares of Turn Therapeutics to a "hold" rating in a report on Tuesday, July 21st. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $8.00.

Turn Therapeutics Trading Down 5.2%

NASDAQ TTRX opened at $12.69 on Friday. The firm has a market cap of $378.04 million and a price-to-earnings ratio of -43.76. The firm has a 50 day simple moving average of $9.71 and a 200-day simple moving average of $6.26. Turn Therapeutics has a one year low of $2.57 and a one year high of $26.50. The company has a debt-to-equity ratio of 8.83, a quick ratio of 1.19 and a current ratio of 1.19.

Turn Therapeutics (NASDAQ:TTRX - Get Free Report) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.20) earnings per share for the quarter. Equities research analysts anticipate that Turn Therapeutics will post -0.4 EPS for the current fiscal year.

Institutional Investors Weigh In On Turn Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Ieq Capital LLC acquired a new stake in Turn Therapeutics during the 2nd quarter worth approximately $1,660,000. Millennium Management LLC acquired a new position in Turn Therapeutics during the fourth quarter valued at approximately $377,000. DDFG Inc grew its stake in Turn Therapeutics by 34.9% during the first quarter. DDFG Inc now owns 70,534 shares of the company's stock worth $226,000 after buying an additional 18,246 shares during the period. Wellington Shields & Co. LLC purchased a new stake in Turn Therapeutics during the fourth quarter worth approximately $259,000. Finally, BlackRock Inc. acquired a new stake in shares of Turn Therapeutics in the second quarter worth $282,000.

Turn Therapeutics Company Profile

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.